Annals of Surgical Oncology

, Volume 15, Issue 10, pp 2842–2846 | Cite as

Older Age and Larger Tumor Size Predict Malignancy in Hürthle Cell Neoplasms of the Thyroid

  • Yi Wei Zhang
  • David Yu Greenblatt
  • Daniel Repplinger
  • Anna Bargren
  • Joel T. Adler
  • Rebecca S. Sippel
  • Herbert Chen
Endocrine Tumors

Abstract

Background

Hürthle cell neoplasms (HCNs) are rare tumors of the thyroid gland. The definitive treatment for Hürthle cell carcinoma (HCC) is total thyroidectomy, while thyroid lobectomy is adequate for Hürthle cell adenoma (HCA). However, differentiating HCC from HCA either before or during surgery is a challenge. The purpose of this study was to identify factors that predict malignancy in patients with HCN.

Methods

Between May 1994 and January 2007, 1,199 patients underwent thyroid surgery at an academic medical center. Medical records of 55 consecutive patients who underwent thyroid resections for the preoperative diagnosis of HCN were reviewed.

Results

Of the 55 patients with HCN, 46 (84%) had adenomas and 9 (16%) had carcinomas. Patients with HCC were significantly older than those with HCA (66 ± 6 years versus 53 ± 2 years, P = 0.01). Patients with carcinoma also had significantly larger thyroid nodules (4.5 ± 0.7 cm versus 2.5 ± 0.2 cm, P < 0.001). All HCNs less than 2 cm in diameter were benign. The malignancy rate increased with nodule size: 18% of nodules measuring 2–4 cm, and 44% of those larger than 4 cm were HCC. One patient with HCC had recurrence of the disease, but there were no disease-related deaths.

Conclusion

Advanced patient age and larger nodule size are two important factors that predict malignancy in patients with HCN. In patients with these and other known risk factors for HCC, total thyroidectomy should be considered.

Keywords

Hürthle cell neoplasms Hürthle cell carcinoma Hürthle cell adenoma Malignant thyroid neoplasms Thyroid surgery Fine-needle aspiration biopsy 

References

  1. 1.
    Chen H, Udelsman R. (2005) Hurthle cell adenoma, carcinoma. In: Clark OH, Duh QY (eds). Textbook of endocrine surgery, 2nd edition. W. B. Saunders, Philadelphia PA, pp 123–8Google Scholar
  2. 2.
    Chen H, Nicol TL, Zeiger MA, et al. Hurthle cell neoplasms of the thyroid: are there factors predictive of malignancy? Ann Surg 1998;227:542–6PubMedCrossRefGoogle Scholar
  3. 3.
    Gosain AK, Clark OH. Hurthle cell neoplasms. Malignant potential. Arch Surg 1984;119:515–9PubMedGoogle Scholar
  4. 4.
    Azadian A, Rosen IB, Walfish PG, et al. Management considerations in Hurthle cell carcinoma. Surgery 1995;118:711–4. discussion 714–5PubMedCrossRefGoogle Scholar
  5. 5.
    Greenblatt DY, Woltman T, Harter J, et al. Fine-needle aspiration optimizes surgical management in patients with thyroid cancer. Ann Surg Oncol 2006;13:859–63PubMedCrossRefGoogle Scholar
  6. 6.
    Chen H, Nicol TL, Udelsman R. Follicular lesions of the thyroid. does frozen section evaluation alter operative management? Ann Surg 1995;222:101–6PubMedCrossRefGoogle Scholar
  7. 7.
    McHenry CR, Sandoval BA. Management of follicular and hurthle cell neoplasms of the thyroid gland. Surg Oncol Clin North Am 1998;7:893–910Google Scholar
  8. 8.
    Elliott DD, Pitman MB, Bloom L, et al. Fine-needle aspiration biopsy of hurthle cell lesions of the thyroid gland: a cytomorphologic study of 139 cases with statistical analysis. Cancer 2006;108:102–9PubMedCrossRefGoogle Scholar
  9. 9.
    Rosen IB, Luk S, Katz I. Hurthle cell tumor behavior: dilemma and resolution. Surgery 1985;98:777–83PubMedGoogle Scholar
  10. 10.
    Arganini M, Behar R, Wu TC, et al. Hurthle cell tumors: a twenty-five-year experience. Surgery 1986;100:1108–15PubMedGoogle Scholar
  11. 11.
    Carcangiu ML, Bianchi S, Savino D, et al. Follicular Hurthle cell tumors of the thyroid gland. Cancer 1991;68:1944–53PubMedCrossRefGoogle Scholar
  12. 12.
    McDonald MP, Sanders LE, Silverman ML, et al. Hurthle cell carcinoma of the thyroid gland: prognostic factors and results of surgical treatment. Surgery 1996;120:1000–4. discussion 1004–5PubMedCrossRefGoogle Scholar
  13. 13.
    Besic N, Hocevar M, Zgajnar J, et al. Aggressiveness of therapy and prognosis of patients with Hurthle cell papillary thyroid carcinoma. Thyroid 2006;16:67–72PubMedCrossRefGoogle Scholar
  14. 14.
    Sanders LE, Silverman M. Follicular and Hurthle cell carcinoma: predicting outcome and directing therapy. Surgery 1998;124:967–74PubMedGoogle Scholar
  15. 15.
    Watson RG, Brennan MD, Goellner JR, et al. Invasive Hurthle cell carcinoma of the thyroid: natural history and management. Mayo Clin Proc 1984;59:851–5PubMedGoogle Scholar
  16. 16.
    Besic N, Vidergar-Kralj B, Frkovic-Grazio S, et al. The role of radioactive iodine in the treatment of Hurthle cell carcinoma of the thyroid. Thyroid 2003;13:577–84PubMedCrossRefGoogle Scholar
  17. 17.
    Callcut RA, Selvaggi SM, Mack E, et al. The utility of frozen section evaluation for follicular thyroid lesions. Ann Surg Oncol 2004;11:94–8PubMedCrossRefGoogle Scholar
  18. 18.
    Ron E, Modan B, Preston D, et al. Thyroid neoplasia following low-dose radiation in childhood. Radiat Res 1989;120:516–31PubMedCrossRefGoogle Scholar
  19. 19.
    Thompson NW, Dunn EL, Batsakis JG, et al. Hurthle cell lesions of the thyroid gland. Surg Gynecol Obstet 1974;139:555–60PubMedGoogle Scholar
  20. 20.
    Johnson TL, Lloyd RV, Burney RE, et al. Hurthle cell thyroid tumors an immunohistochemical study. Cancer 1987;59:107–12PubMedCrossRefGoogle Scholar
  21. 21.
    Taneri F, Tekin E, Salman B, et al. Huerthle cell neoplasms of the thyroid: predicting malignant potential. Endocr Regul 2000;34:19–21PubMedGoogle Scholar
  22. 22.
    Lopez-Penabad L, Chiu AC, Hoff AO, et al. Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 2003;97:1186–94PubMedCrossRefGoogle Scholar
  23. 23.
    Giorgadze T, Rossi ED, Fadda G, et al. Does the fine-needle aspiration diagnosis of “Hurthle-cell neoplasm/follicular neoplasm with oncocytic features” denote increased risk of malignancy? Diagn Cytopathol 2004;31:307–12PubMedCrossRefGoogle Scholar
  24. 24.
    Pisanu A, Sias L, Uccheddu A. Factors predicting malignancy of Hurthle cell tumors of the thyroid: influence on surgical treatment. World J Surg 2004;28:761–5PubMedCrossRefGoogle Scholar
  25. 25.
    Melck A, Bugis S, Baliski C, et al. Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm. Am J Surg 2006;191:593–7PubMedCrossRefGoogle Scholar
  26. 26.
    Paunovic I, Krgovic K, Tatic S, et al. Surgery for thyroid Hurthle cell tumours–a single institution experience. Eur J Surg Oncol 2006;32:458–61PubMedCrossRefGoogle Scholar
  27. 27.
    Gauger PG, Reeve TS, Delbridge LW. Intraoperative decision making in follicular lesions of the thyroid: is tumor size important? J Am Coll Surg 1999;189:253–8PubMedCrossRefGoogle Scholar
  28. 28.
    McHenry CR, Thomas SR, Slusarczyk SJ, et al. Follicular or Hurthle cell neoplasm of the thyroid: can clinical factors be used to predict carcinoma and determine extent of thyroidectomy? Surgery 1999;126:798–802. discussion 802–4PubMedGoogle Scholar
  29. 29.
    Sugino K, Ito K, Mimura T, et al. Hurthle cell tumor of the thyroid: analysis of 188 cases. World J Surg 2001;25:1160–3PubMedGoogle Scholar
  30. 30.
    Chao TC, Lin JD, Chen MF. Surgical treatment of Hurthle cell tumors of the thyroid. World J Surg 2005;29:164–8PubMedCrossRefGoogle Scholar
  31. 31.
    Alaedeen DI, Khiyami A, McHenry CR. Fine-needle aspiration biopsy specimen with a predominance of Hurthle cells: a dilemma in the management of nodular thyroid disease. Surgery 2005;138:650–6. discussion 656–7PubMedCrossRefGoogle Scholar
  32. 32.
    Papotti M, Torchio B, Grassi L, et al. Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid. Am J Surg Pathol 1996;20:686–94PubMedCrossRefGoogle Scholar
  33. 33.
    Erickson LA, Jin L, Goellner JR, et al. Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid. Mod Pathol 2000;13:186–92PubMedCrossRefGoogle Scholar
  34. 34.
    Hoos A, Stojadinovic A, Singh B, et al. Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol 2002;160:175–83PubMedGoogle Scholar
  35. 35.
    Finley DJ, Zhu B, Fahey TJ 3rd Molecular analysis of Hurthle cell neoplasms by gene profiling. Surgery 2004;136:1160–8PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • Yi Wei Zhang
    • 1
  • David Yu Greenblatt
    • 1
  • Daniel Repplinger
    • 1
  • Anna Bargren
    • 1
  • Joel T. Adler
    • 1
  • Rebecca S. Sippel
    • 1
  • Herbert Chen
    • 1
  1. 1.Section of Endocrine Surgery, Department of SurgeryUniversity of WisconsinMadisonUSA

Personalised recommendations